Is AbbVie Inc. (ABBV) Expanding Its Oncology Pipeline With New BPDCN Treatment Approval?

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) is among the best immunology stocks.

TheFly reported on May 27 that ABBV announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for adults diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and fast-progressing blood cancer with limited available therapies. The authorization was supported by findings from the Phase 1/2 CADENZA study, which evaluated the treatment’s safety and clinical activity in BPDCN patients.

Trial results showed strong and lasting responses among newly diagnosed participants, including a 69.7% composite complete response rate and a median response duration of 9.7 months. Patients with relapsed or refractory disease recorded a 15.7% composite complete response rate with a 9.2-month median duration of response. Several patients later proceeded to stem cell transplantation following treatment.

Is AbbVie Inc. (ABBV) Expanding Its Oncology Pipeline With New BPDCN Treatment Approval?

Separately, on May 22, AbbVie Inc. (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a favorable recommendation for Maviret, the company’s oral pangenotypic antiviral therapy for acute hepatitis C. The recommendation covers treatment for adults as well as children aged 3 years and older. ABBV stated that a final decision from the European Commission is anticipated during the third quarter of 2026. If authorized, Maviret would become approved in the European Union for both acute and chronic hepatitis C infections, potentially expanding its treatment use across a broader patient population.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company and a leader in immunology. Spun off from Abbott Laboratories in 2013, it develops treatments for immune-mediated diseases across rheumatology, dermatology, and gastroenterology, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1